Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Randomized, Comparative Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT07553988 is registered in ClinicalTrials.gov with R-Pharm International, LLC as lead sponsor.

NCT NCT07553988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07553988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Randomized, Comparative Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
Lead sponsor
R-Pharm International, LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 24, 2024
Completion date
May 9, 2027
Enrollment
120 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer